Nov 10, 2025 07:40AM ArriVent BioPharma (AVBP) PT Raised to $47 at Clear Street

Aug 12, 2025 06:41AM ArriVent BioPharma (AVBP) PT Raised to $42 at H.C. Wainwright

Aug 11, 2025 04:21PM ArriVent BioPharma, Inc. (AVBP) Misses Q2 EPS by 14c

Jul 22, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on ArriVent BioPharma (AVBP)

Jul 21, 2025 09:12AM Oppenheimer Reiterates Outperform Rating on ArriVent BioPharma (AVBP)

Jul 10, 2025 06:23AM Goldman Sachs Resumes ArriVent BioPharma (AVBP) at Buy

Jul 3, 2025 06:12AM Clear Street Reiterates Buy Rating on ArriVent BioPharma (AVBP)

Jul 1, 2025 04:05PM ArriVent BioPharma (AVBP) Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jun 30, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on ArriVent BioPharma (AVBP)

Jun 24, 2025 04:20PM Clear Street Starts ArriVent BioPharma (AVBP) at Buy

Jun 23, 2025 12:47PM ArriVent BioPharma (AVBP) PT Raised to $40 at Citi, Adding 90d Upside Catalyst Watch

Jun 23, 2025 07:03AM ArriVent BioPharma (AVBP) Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer

May 14, 2025 07:52AM ArriVent BioPharma (AVBP) PT Raised to $40 at H.C. Wainwright

May 12, 2025 08:01AM ArriVent BioPharma, Inc. (AVBP) Misses Q1 EPS by 117c

Apr 28, 2025 08:02AM ArriVent BioPharma (AVBP) Appoints Merdad Parsey to its Board

Mar 20, 2025 02:20AM B.Riley Starts ArriVent BioPharma (AVBP) at Buy

Mar 7, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on ArriVent BioPharma (AVBP)

Mar 3, 2025 01:39PM Oppenheimer Reiterates Outperform Rating on ArriVent BioPharma (AVBP)

Feb 3, 2025 07:08AM ArriVent BioPharma (AVBP) Files $250M Mixed Shelf

Nov 15, 2024 07:13AM ArriVent BioPharma, Inc. (AVBP) Misses Q3 EPS by 7c

Sep 10, 2024 11:49AM ArriVent BioPharma (AVBP) PT Raised to $36 at Citi

Sep 10, 2024 06:39AM ArriVent BioPharma (AVBP) PT Raised to $36 at H.C. Wainwright

Sep 10, 2024 06:22AM ArriVent BioPharma (AVBP) PT Raised to $39 at Oppenheimer

Sep 9, 2024 12:07PM ArriVent BioPharma (AVBP) Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Con

Aug 16, 2024 06:42AM ArriVent BioPharma (AVBP) PT Raised to $30 at H.C. Wainwright

Aug 12, 2024 08:11AM ArriVent BioPharma (AVBP) to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer

Jul 22, 2024 07:05AM Oppenheimer Starts ArriVent BioPharma (AVBP) at Outperform